Role of polymorphisms in factor V (FV leiden), prothrombin, plasminogen activator inhibitor type-1 (PAI-1), methylenetetrahydrofolate reductase (MTHFR) and cystathionine β-synthase (CBS) genes as risk factors for thrombophilias

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 997-1006

  Miranda Vilela, A L ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Coagulation factors; Fibrinolysis; Gene polymorphisms; Hypercoagulability; Thrombophilias; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7A; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; ENOXAPARIN; FOLIC ACID; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METFORMIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; PYRIDOXINE; RECOMBINANT HIRUDIN; STREPTOKINASE; WARFARIN;

ARTERY THROMBOSIS; BASE PAIRING; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; ENVIRONMENTAL FACTOR; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; HEPARIN INDUCED THROMBOCYTOPENIA; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOCYSTINURIA; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; PATHOGENESIS; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; THROMBOPHILIA; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

ANIMALS; CYSTATHIONINE BETA-SYNTHASE; FACTOR V; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROTHROMBIN; THROMBOPHILIA; THROMBOSIS;

EID: 84866459949     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712802762338     Document Type: Review

References (69)

1. Fonseca, A.G.; Amaro, M. Thrombophilias: the importance of clinical screening in thromboembolic disease. Rev. Soc. Port. Med. Int., 2008, 15(4), 284-290.
2. Guimarães, S.P.; Soares, J.B.B.; Oliveira, V.C.; Pardini, V.C.; Ferreira, A.C.S. Predisposing thrombophilic mutations in individuals with clinical suspicion of thrombosis from Minas Gerais, Brazil. Rev. Bras. Hematol. Hemoter., 2009, 31(1), 19-24.
3. Franco, R.F. Inherited thrombophilias. Medicina, 2001, 34, 248-257.
4. D'Amico, E.A. Trombofilia: Quando Suspeitar e Como Investigar? Rev. Assoc. Med. Bras., 2003, 49(1), 7-8.
5. Garcia, A.A.; Franco, R.F. Acquired Thrombophilias. Medicina, 2001, 34, 258-268.
6. Fritsma, G.A.; Marques, M.B. Hematology: Clinical Principles and Applications; Saunders; Elsevier: St. Louis, Missouri, 2007, pp. 605-629.
7. Previtali, E.; Bucciarelli, P.; Passamonti, S.M.; Martinelli, I. Risk factors for venous and arterial thrombosis. Blood Transfus., 2011, 9, 120-138.
8. Ramos, C.P.S.; Campos, J.F.; Melo, F.C.B.C.; das Neves, W.B.; dos Santos, M.E.; Araújo, F.A.; Melo, R.A.M. Frequency of factor V Leiden in individuals under thrombophilia investigation, Recife, Pernambuco, Brazil. Rev. Bras. Hematol. Hemoter., 2006, 28(2), 131-134.
9. Duque, F.L.V.; Mello, N.A. Thrombogenesis - Thrombophilia. J. Vasc. Br. 2003, 2(2), 105-118.
10. Lim, W.; Crowther, M.A.; Eikelboom, J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA, 2006, 295, 1050-1057.
11. Stec, J.J.; Silbershatz, H.; Tofler, G.H.; Matheney, T.H.; Sutherland, P.; Lipinska, I.; Massaro, J.M.; Wilson, P.F.; Muller, J.E.; D'Agostino, R.B. Sr. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation, 2000, 102(14), 1634-1638.
12. Machlus, K.R.; Cardenas, J.C.; Church, F.C.; Wolberg, A.S. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood, 2011, 117(18), 4953-4963.
13. Rang, H.P.; Dale, M.M., Ritter, J.M., Moore, P.K. Farmacologia. 3rd ed.; Elsevier Ed. Ltd.: Rio de Janeiro, 2004.
14. Jung, W.K.; Jo, H.Y.; Qian, Z.J.; Jeong, Y.J.; Park, S.G.; Choi, I.W.; Kim, S.K. A novel anticoagulant protein with high affinity to blood coagulation factor Va from Tegillarca granosa. J. Biochem. Mol. Biol., 2007, 40(5), 832-838.
15. Guyton, A.C.; Hall, J.E. Tratado de Fisiologia Médica. 11th ed.; Elsevier Ed. Ltda: Rio de Janeiro, 2006.
16. Fritsma, M.G.; Fritsma, G.A. Hematology: Clinical Principles and Applications; Saunders; Elsevier: St. Louis, Missouri, 2007, pp. 571-587.
17. Duga, S.; Asselta, R.; Tenchini, M.L. Molecules in focus: Coagulation factor V. Int. J. Biochem. Cell Biol., 2004, 36, 1393-1399.
18. Bertina, R.M.; Koelemar, B.P.C.; Koster, T.; Rosendaal, F.R.; Dirven, R.J.; De Ronde, H.; Van Der Velden, P.A.; Reitsma, P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 1994, 369, 64-67.
19. Buchanan, G.S.; Rodgers, G.M.; Branch D.W. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. Best Pract. Res. Clin. Obstet. Gynaecol. 2003, 17(3), 397-411.
20. Nurk, E.; Tell, G.S.; Refsum, H.; Ueland, P.M.; Vollset, S.E. Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. QJM, 2006, 99(5), 289-298.
21. Kujovich, J.L. Factor V Leiden thrombophilias. Genet. Med., 2011, 13(1), 1-16.
22. Delrio-Lafreniere, S.A.; Mcglennen, R.C. Simultaneous allelespecific amplification: a strategy using modified primer-template mismatches for SNP detection-application to prothrombin 20210A (factor II) and factor V Leiden (1691A) gene mutations. Mol. Diagn., 2001, 6(3), 201-209.
23. Poort, S.R.; Rosendaal, F.R.; Reitsma, P.H.; Bertina, R.M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 1996, 88, 3698-3703.
24. Degen, S.J.F.; Davie, E.W. Nucleotide sequence of the gene for human prothrombin. Biochemistry, 1987, 26(19), 6165-6177.
25. Shankar, V.K.; Handa, A.; Hands, L. Endogenous heparin activity is decreased in peripheral arterial occlusive disease. J. Vasc. Surg., 2008, 47(5), 1033-1038.
26. Lancellotti S, de Cristofaro R. Congenital prothrombin deficiency. Semin. Thromb. Hemost., 2009, 35(4), 367-381.
27. Martinelli I, Battaglioli T, Razzari C, Mannucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J. Thromb. Haemost., 2007, 5(1), 98-101.
28. Lijfering, W.M.; Middeldorp, S.; Veeger, N.J.G.M.; Hamulyák, K.; Prins, M.H.; Büller, H.R.; van der Meer, J. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and Prothrombin G20210A. Circulation, 2010, 121, 1706-1712.
29. Kujovich, J.L. Prothrombin-related Thrombophilia. Available: http://www.ncbi.nlm.nih.gov/books/NBK1148 [Accessed September 20, 2011].
30. Greinacher, A.; Warkentin, T.E. The direct thrombin inhibitor hirudin. Thromb. Haemost., 2008, 99, 819-829.
31. Magalhães, V.; Veiga-Malta, I.; Almeida, M.R.; Baptista, M.; Ribeiro, A.; Trieu-Cuot, P.; Ferreira, P. Interaction with human plasminogen system turns on proteolytic activity in Streptococcus agalactiae and enhances its virulence in a mouse model. Microbes Infect., 2007, 9(11), 1276-1284.
32. Fay, W.P.; Parker, A.C.; Condrey, L.R.; Shapiro, A.D. Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene. Blood, 1997, 90, 204-208.
33. Annichino-Bizzacchi, J.M.; Pugliese, L.; Arruda, V.R. A rapid detection method for PAI-1 promoter insertion/deletion polymorphism (4G/5G). Genet. Mol. Biol., 1998, 21(3), 315-316.
34. Madách, K.; Aladzsity, I.; Szilágyi, Á. Fust, G.; Gál, J.; Pénzes, I.; Prohászka, Z. Research 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Crit. Care, 2010, 14, R79.
35. Dawson, S.J.; Wiman, B.; Hamsten, A.; Green, F.; Humphries, S.; Henney, A.M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem., 1993, 268(15), 10739-10745.
36. Eriksson, P.; Kallin, B.; Van T'hooft, F.M.; Bavhenolm, P.; Hamsten, A. Allelic-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA, 1995, 92, 1851-1855.
37. Margaglione, M.; Cappucci, G.; Colaizzo, D.; Giuliani, N.; Vecchione, G.; Grandone, E.; Pennelli, O.; Di Minno, G. The PAI- 1 Gene Locus 4G/5G Polymorphism Is Associated With a Family History of Coronary Artery Disease. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 152-156.
38. Tsantes, A.E.; Nikolopoulos, G.K.; Bagos, P.G.; Bonovas, S.; Kopterides, P.; Vaiopoulos, G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb. Res., 2008, 122, 736-742.
39. Sartori, M.T., Danesin, C., Saggiorato, G., Tormene, D., Simioni, P., Spiezia, L., Patrassi, G.M., Girolami, A. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin. Appl. Thromb. Hemost. 2003, 9(4), 299-307.
40. Seguí, R., Estellés, A., Mira, Y., España, F., Villa, P., Falcó, C., Vayá, A., Grancha, S., Ferrando, F., Aznar, J. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br. J. Haematol. 2000, 111(1), 122-128.
41. Boekholdt, S.M.; Bijsterveld, N.R.; Moons, A.H.M.; Levi, M.; Büller, H.R.; Peters, R.J.G. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A Systematic Review. Circulation, 2001, 104, 3063-3068.
42. Kohler, H.P.; Grant, P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med., 2000, 342(24), 1792-1801.
43. Lee, M.H.; Vosburgh, E.; Anderson, K.; McDonagh, J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood, 1993, 81, 2357-2362.
44. Grebenchtchikov, N.; Maguire, T.M.; Riisbro, R.; Geurts-Moespot, A.; O'Donovan, N.; Schmitt, M.; McGreal, G.; McDermott, E.; O'Higgins, N.; Brünner, N.; Sweep, C.G.; Duffy, M.J. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol. Rep. 2005, 14(1), 235-259.
45. Mlynarska, A.; Waszyrowski, T.; Kasprzak, J.D. Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene. J. Thromb. Haemost., 2006, 4(6),1361-1366.
46. Dossenbach-Glaninger, A.; van Trotsenburg, M.; Dossenbach, M.; Oberkanins, C.; Moritz, A.; Krugluger, W.; Huber, J.; Hopmeier, P. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin. Chem., 2003, 49(7), 1081-1086.
47. Georgia Reproductive Specialists. Thrombophilia: Another Factor to Consider in Cases of Recurrent Pregnancy Loss. 2007. Available at: http://www.ivf.com/thrombophilia.html [Accessed October 12, 2011].
48. Duthie, S.J.; Narayanan, S.; Brand, G.M.; Pirie, L.; Grant, G. Impact of folate deficiency on DNA stability. J. Nutr., 2002, 132, 2444S-2449S.
49. Moon, H.W.; Kim, T.Y.; Oh, B.R.; Min, H.C.; Cho, H.I.; Bang, S.M.; Lee, J.H.; Yoon, S.S.; Lee, D.S. MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea. Leuk Res., 2007, 31, 1213-1217.
50. Bydlowski, S.P.; Magnanelli, A.C.; Chamone, D.A.F. Hiperhomocisteinemia e Doenças Vaso-Oclusivas. Arq. Bras. Cardiol., 1998, 71(1): 69-76.
51. Persuhn, D.C.; Sack, D.; Schütz, T.L.; Melo, S.S. Prevalence of MTHFR G1793A polimorfism in elderly- Itajaí, (SC). Rev. Bras. Anal. Clin., 2006, 38(1), 47-50.
52. Sachdev, P. Homocisteína e transtornos psiquiátricos. Rev. Bras. Psiquiatr., 2004, 26(1), 50-56.
53. Marcucci, R.; Giusti, B; Betti, I.; Evangelisti, L.; Fedi, S.; Sodi, A.; Cappelli, S.; Menchini, U.; Abbate, R.; Prisco, D. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thrombosis Res., 2003, 110, 7-12.
54. Misawa, A.K.; Suzuki, H.; Maia Júnior, O.O.; Bonanomi, M.T.B.C.; Melo, C.S.N. Obstrução arterial retiniana periférica associada com hiperhomocisteinemia: relato de caso. Arq Bras Oftalmol., 2008, 71(5), 729-733.
55. Tonetti, C.; Saudubray, J.M.; Echenne, B.; Landrieu, P.; Giraudier, S.; Zittoun, J. Relations between molecular and biological abnormalities in 11 families from siblings affected with methylenetetrahydrofolate reductase deficiency. Eur. J. Pediatr., 2003, 162, 466-475.
56. Frosst, P.; Blom, H.J.; Milos, R.; Goyette, P.; Sheppard, C.A.; Matthews, R.G.; Boers, G.J.H.; Den Heijer, M.; Kluijtmans, L.A.J.; Van Den Heuve, L.P.; Rozen, R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet., 1995, 10, 111-113.
57. Makris, M. Hyperhomocysteinemia and thrombosis. Clin. Lab. Haem., 2000, 22(3), 133-143.
58. van der Put, N.M.J.; Gabreëls, F.; Stevens, B.E.M.; Smeitink, J.A.M.; Trijbels, F. J.M.; Eskes, T.K.A.B.; van den Heuvel, L.P.; Blom, H.J. A second mutation in the methylenetetrahydrofolate reductase gene: an additional factor for neuraltube defects? Am. J. Hum. Genet., 1998, 62, 1044-1051.
59. Franco, R.F.; Morelli, V.; Lourenço, D.; Maffei, F.H.; Tavella, M.H.; Piccinato, C. E.; Thomazini, I.A.; Zago, M.A. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease. Br. J. Haematol., 1999, 105, 556-559.
60. Genetics Home Reference. CBS gene. Available: http://ghr.nlm.nih.gov/gene=cbs [Accessed September 14, 2011].
61. CBS Mutation Database. Available: http://cbs.lf1.cuni.cz/index.php [Accessed September 16, 2011].
62. Hu, F.L.; Gu, Z.; Kozich, V.; Kraus, J.P.; Ramesh, V.; Shih, V.E. Molecular basis of cystathionine ß-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria Hum. Mol. Genet. 1993, 2, 1857-1860.
63. Tsai, M.Y.; Garg, U.; Key, N.S.; Hanson, N.Q.; Suh, A.; Schwichtenberg, K.A. Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis, 1996, 122, 69-77.
64. Tsai, M.Y.; Bignell, M.; Schwichtenberg, K.; Hanson, N.Q. High prevalence of a mutation in the cystathionine beta-synthase gene. Am. J. Hum. Genet. 1996, 59, 1262-1267.
65. Franco, R.F.; Elion, J.; Lavinha, J.; Krishnamoorthy, R.; Tavella, M.H.; Zago, M. A. Heterogeneous Ethnic Distribution of the 844ins68 in the Cystathionine ß-Synthase Gene. Hum. Hered., 1998, 48, 338-342.
66. Franco, R.F.; Reitsma, P.H. Genetic risk factors of venous thrombosis. Hum. Genet., 2001, 109, 369-384.
67. Kraus, J.P.; Janosik, M.; Kozich, V.; Mandell, R.; Shih, V.; Sperandeo, M.P.; Sebastio, G.; De Franchis, R.; Andria, G.; Kluijtmans, L.A.J.; Blom, H.; Boers, G.H.J.; Gordon, R.B.; Kamoun, P.; Tsai, M.Y.; Kruger, W.D.; Koch, H.G.; Ohura, T.; Gaustadnes, M. Cystathionine beta-synthase mutations in homocystinuria. Hum. Mutat., 1999, 13, 362-375.
68. Bonini-Domingos, C.R.; Zamaro, P. J. A.; Mendiburu, C.F.; Sanches, F.E.; Cintra, J.R.; Godoy, J.M.P.; Mattos, L.C. Frequência da mutação 844ins68 do gene da cistationina β-sintetase em pacientes com trombose venosa profunda. Rev. Bras. Hematol. Hemoter., 2005, 27(1), 12-15.
69. Maron, B.A.; Loscalzo, J. The Treatment of Hyperhomocysteinemia. Annu. Rev. Med., 2009, 60, 39-54.